Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Intercell
company
About
Intercell AG, a biotechnology company, engages in the design and development of vaccines for the prevention and treatment of infectious.
- 251 - 500
Highlights
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $50M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 1998
- Number Of Employee
- 251 - 500
- Operating Status
- Active
Intercell AG, a biotechnology company, engages in the design and development of vaccines for the prevention and treatment of infectious diseases. It discovers and develops antigens and adjuvants, which are derived from its proprietary technology platforms. The company was founded in 1998 and is headquartered in Vienna, Austria.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$50M
Intercell has raised a total of
$50M
in funding over 2 rounds. Their latest funding was raised on
Jul 18, 2003 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 18, 2003 | Series C | $50M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Intercell is funded by 1 investors.
Nomura International
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Nomura International
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
